Form 4: Halozyme CEO Helen Torley Executes Pre-Planned Stock Sales Following Option Exercises

Halozyme Therapeutics, Inc. President and CEO Helen Torley completed a series of pre-arranged option exercises and subsequent stock sales totaling 60,000 shares in late June 2025, as detailed in a recent SEC Form 4 filing.

Summary

• Helen Torley, who serves as President, CEO, and Director of Halozyme Therapeutics, Inc. (HALO), reported multiple transactions involving the company's common stock.
• Between June 20, 2025, and June 24, 2025, Ms. Torley exercised options to acquire a total of 60,000 shares of common stock at a fixed exercise price of $8.11 per share.
• Concurrently with the option exercises, she sold a total of 60,000 shares of common stock in the open market.
• The sales occurred at weighted average prices ranging from $52.573 to $53.911 per share across the different transaction dates.
• All reported transactions were conducted pursuant to a Rule 10b5-1 trading plan, which was adopted by Ms. Torley on March 21, 2025.
• Following these transactions, Ms. Torley's direct beneficial ownership of common stock decreased from 753,719 shares to 733,719 shares, and her beneficial ownership of derivative securities (options) decreased from 356,569 to 316,569.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. While insider selling can sometimes be viewed negatively, the fact that these transactions were pre-planned under a Rule 10b5-1 plan mitigates concerns about their implications for the company's immediate prospects. The significant profit realized by the insider from the option exercises is a positive for the individual.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned liquidity event rather than a reaction to new, potentially negative, company information.
• The sales were executed at significantly higher prices (ranging from $52.573 to $53.911) compared to the option exercise price of $8.11, demonstrating a substantial realized gain for the insider.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived by the market as a reduction in the insider's direct equity alignment with shareholders, though the impact is mitigated by the 10b5-1 plan.

Future Outlook

NA

Management Comments

• The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025, in accordance with Rule 10b5-1.

Industry Context

NA

Stakeholder Impact

• Shareholders: May view the insider sale with slight caution, although the pre-planned nature under a Rule 10b5-1 plan generally reduces concerns about its implications for the company's future performance. The sale at high prices indicates the insider is realizing significant gains.

Key Dates

Keywords

Halozyme Therapeutics, HALO, SEC Form 4, Insider Trading, Stock Options, Executive Compensation, Helen Torley, Rule 10b5-1 Plan, Stock Sale, Beneficial Ownership